Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

THIRD-PARTY REVIEW PROVISIONS OF S 1477 REMAIN CONCERN, KENNEDY STAFFER SAYS;FDA COMMISSIONER TERM LIMITS LIKELY WILL TARGET KESSLER, STAFFER PREDICTS

Executive Summary

Third-party review mandates in Sen. Kassebaum's (R-Kan.) FDA reform bill (S 1477) are "more worrisome" than the bill's provision for expedited approval for drugs cleared in the European Union, said Pearl O'Rourke, MD, Robert Wood Johnson fellow to Sen. Kennedy (D-Mass.) on the Labor & Human Resources Committee. She made her remarks at the University of North Carolina-Chapel Hill's Center for Pharmaceutical Outcomes Research conference March 31.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel